The Food and Drug Administration does not often warn CBD producers for making false or unsubstantiated health claims. However, when the FDA does so, it grabs the headlines. The latest victims to get CBD FDA warning letters are seven cannabidiol product vendors that made claims over CBD for coronavirus disease. The letters come as an element of the enforcement action from the Food and Drug Administration and the Federal Trade Commission.
The enforcement action totals around 500 warning letters to companies after the beginning of the coronavirus epidemic. The FDA CBD warning letters concern the companies that make medical devices, PPE, dietary supplements, and other items. The companies also make an array of cannabidiol items, including full-spectrum cannabidiol blends and CBD isolate products. For the uninitiated, the term full-spectrum refers to an industrial hemp derivative with non-CBD cannabinoids, terpenes, essential oils and so forth. On the other hand, the word isolate refers to an item with only cannabidiol as a phytocannabinoid.
A Wide Range Of Claims That Do Not Comply With FDA Rules And Regulations
As per the letters, these are among the things published on the social media web pages and the websites of the seven companies.
- More and more researchers and doctors are looking at cannabidiol for coronavirus disease. Cannabidiol may aid doctors in dealing with COVID-19 symptoms and mitigating the pulmonary damage from the virus in the long run.
- Studies demonstrate that cannabis compounds keep coronavirus-affected cells from getting replicated.
- Cannabis compounds can also prevent the infection that comes from coronavirus and that induces COVID-19 after blocking its entrance into cells.
The Food and Drug Administration offers firms that make those kinds of claims two days to react to the letters. On the other hand, the Federal Trade Commission is relatively less lenient. Why? Because the FTC requires those firms to stop making the health claims soon after getting the letters and may slap each company with a fine of $46,517 for its violation.
CBD marketers are yet to benefit from the epidemic identically to how several dietary supplement vendors have gained, particularly the companies marketing any products with immune health components. It has made some companies expand their product lines to include items targeted at human immune support.
It is not the first time that the Food and Drug Administration has warned companies for violating its rules and regulations.